Retinal Detachment

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Retinal Detachment

MalaCards integrated aliases for Retinal Detachment:

Name: Retinal Detachment 57 12 29 54 6 42 44 15 17 70
Retinal Detachments 15



57 (Updated 05-Apr-2021)
autosomal dominant


retinal detachment:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:5327
OMIM® 57 180050
ICD9CM 34 361.9
MeSH 44 D012163
NCIt 50 C26874
SNOMED-CT 67 155103005
ICD10 32 H33.0 H33.2
MedGen 41 C0035305
SNOMED-CT via HPO 68 263681008 42059000
UMLS 70 C0035305

Summaries for Retinal Detachment

MedlinePlus : 42 The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. It provides the sharp, central vision needed for reading, driving, and seeing fine detail. A retinal detachment lifts or pulls the retina from its normal position. It can occur at any age, but it is more common in people over age 40. It affects men more than women and whites more than African Americans. A retinal detachment is also more likely to occur in people who Are extremely nearsighted Have had a retinal detachment in the other eye Have a family history of retinal detachment Have had cataract surgery Have other eye diseases or disorders Have had an eye injury Symptoms include an increase in the number of floaters, which are little "cobwebs" or specks that float about in your field of vision, and/or light flashes in the eye. It may also seem like there is a "curtain" over your field of vision. A retinal detachment is a medical emergency. If not promptly treated, it can cause permanent vision loss. If you have any symptoms, see an eye care professional immediately. Treatment includes different types of surgery. NIH: National Eye Institute

MalaCards based summary : Retinal Detachment, also known as retinal detachments, is related to persistent hyperplastic primary vitreous, autosomal recessive and vitreoretinopathy, neovascular inflammatory. An important gene associated with Retinal Detachment is COL2A1 (Collagen Type II Alpha 1 Chain), and among its related pathways/superpathways are ERK Signaling and Degradation of the extracellular matrix. The drugs Bevacizumab and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are retinal detachment and cardiovascular system

OMIM® : 57 Primary or spontaneous detachment of the retina occurs due to underlying ocular disease and often involves the vitreous as well as the retina. The precipitating event is formation of a retinal tear or hole, which permits fluid to accumulate under the sensory layers of the retina and creates an intraretinal cleavage that destroys the neurosensory process of visual reception. Vitreoretinal degeneration and tear formation are painless phenomena, and in most cases, significant vitreoretinal pathology is found only after detachment of the retina starts to cause loss of vision or visual field. Without surgical intervention, retinal detachment will almost inevitably lead to total blindness (summary by McNiel and McPherson, 1971). (180050) (Updated 05-Apr-2021)

Wikipedia : 73 Retinal detachment is a disorder of the eye in which the retina separates from the layer underneath.... more...

Related Diseases for Retinal Detachment

Diseases related to Retinal Detachment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 688)
# Related Disease Score Top Affiliating Genes
1 persistent hyperplastic primary vitreous, autosomal recessive 32.7 TSPAN12 NDP-AS1 NDP ATOH7
2 vitreoretinopathy, neovascular inflammatory 32.7 VEGFA GLUL GFAP
3 kniest dysplasia 32.7 COL9A3 COL2A1 COL11A1
4 stickler syndrome 32.7 COL9A3 COL2A1 COL11A1
5 stickler syndrome, type i 32.5 COL2A1 COL11A1
6 myopia 32.4 VEGFA SERPINF1 RHO COL2A1 COL11A1
7 exudative vitreoretinopathy 3 32.3 TSPAN12 NDP LRP5 FZD4
8 vitreoretinopathy 32.3 TSPAN12 NDP-AS1 NDP LRP5 FZD4 CTNNB1
9 macular holes 32.3 VEGFA SERPINF1 RS1
10 exudative vitreoretinopathy 32.2 VEGFA TSPAN12 NDP-AS1 NDP LRP5 FZD4
11 vitreoretinal degeneration 32.2 COL2A1 COL11A1
12 coats disease 32.2 VEGFA TSPAN12 RS1 RHO NDP LRP5
13 exudative vitreoretinopathy 4 32.2 TSPAN12 NDP LRP5 FZD4
14 microvascular complications of diabetes 5 32.2 VEGFA SERPINF1 RHO PDGFB
15 exudative vitreoretinopathy 2, x-linked 32.1 NDP-AS1 NDP LRP5 FZD4
16 persistent hyperplastic primary vitreous 32.1 VEGFA TSPAN12 NDP-AS1 NDP LRP5 FZD4
17 microphthalmia 32.1 SERPINF1 NDP LRP5 CTNNB1 ATOH7
18 exudative vitreoretinopathy 1 32.0 VEGFA TSPAN12 SERPINF1 RHO PDGFB NDP
19 vitreous detachment 31.9 VEGFA GFAP COL2A1
20 cataract 31.8 VEGFA SERPINF1 RHO CTNNB1 COL2A1 COL11A1
21 macular retinal edema 31.7 VEGFA SERPINF1 RHO
22 strabismus 31.5 RS1 RHO CTNNB1 COL2A1 COL11A1
23 microvascular complications of diabetes 1 31.4 VEGFA SERPINF1 GFAP
24 diabetic macular edema 31.1 VEGFA SERPINF1 GFAP
25 macular degeneration, age-related, 1 31.0 VEGFA SERPINF1 RS1 RHO GFAP
26 eye disease 31.0 VEGFA SERPINF1 RS1 RHO NDP COL2A1
27 retinal vascular disease 31.0 VEGFA TSPAN12 SERPINF1 RHO NDP LRP5
28 chorioretinal scar 31.0 VEGFA RHO
29 vitreous syneresis 31.0 RS1 COL9A3 COL2A1 COL11A1
30 retinal lattice degeneration 30.9 GFAP COL9A3 COL2A1
31 retinal telangiectasia 30.8 VEGFA TSPAN12 NDP FZD4
32 peripheral retinal degeneration 30.8 TSPAN12 RHO COL2A1
33 leukocoria 30.8 TSPAN12 RS1 NDP LRP5 FZD4 ATOH7
34 glaucoma, primary open angle 30.8 VEGFA RHO ATOH7
35 vitreoretinal dystrophy 30.8 RS1 COL11A1
36 brittle bone disorder 30.7 VEGFA SERPINF1 LRP5 CTNNB1 COL2A1 COL11A1
37 retinal perforation 30.7 VEGFA RS1 COL2A1 COL11A1
38 retinitis pigmentosa 30.7 VEGFA SERPINF1 RS1 RHO GLUL GFAP
39 eales disease 30.7 VEGFA SERPINF1
40 pathologic nystagmus 30.7 RHO NDP-AS1 NDP
41 osteoporosis-pseudoglioma syndrome 30.6 NDP LRP5 FZD4 CTNNB1
42 spondyloepiphyseal dysplasia with congenital joint dislocations 30.6 COL9A3 COL2A1 COL11A1
43 norrie disease 30.6 TSPAN12 NDP-AS1 NDP LRP5 FZD4 CTNNB1
44 osteoporosis 30.6 VEGFA NDP LRP5 FZD4 CTNNB1 COL2A1
45 preretinal fibrosis 30.5 VEGFA GFAP
46 marshall syndrome 30.4 COL9A3 COL2A1 COL11A1
47 optic nerve hypoplasia, bilateral 30.4 RHO GLUL GFAP ATOH7
48 multiple epiphyseal dysplasia 30.4 COL9A3 COL2A1 COL11A1
49 bullous retinoschisis 30.4 VEGFA RS1
50 brain edema 30.1 VEGFA GLUL GFAP

Comorbidity relations with Retinal Detachment via Phenotypic Disease Network (PDN):

Hypertension, Essential

Graphical network of the top 20 diseases related to Retinal Detachment:

Diseases related to Retinal Detachment

Symptoms & Phenotypes for Retinal Detachment

Human phenotypes related to Retinal Detachment:

# Description HPO Frequency HPO Source Accession
1 retinal detachment 31 HP:0000541

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
retinal detachment
no myopia

Clinical features from OMIM®:

180050 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Retinal Detachment:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 ATOH7 COL2A1 COL9A3 CTNNB1 FZD4 GFAP
2 nervous system MP:0003631 10.13 ATOH7 COL11A1 COL2A1 CTNNB1 FZD4 GFAP
3 digestive/alimentary MP:0005381 9.97 COL11A1 COL2A1 CTNNB1 FZD4 GFAP PDGFA
4 hearing/vestibular/ear MP:0005377 9.87 COL11A1 COL2A1 COL9A3 CTNNB1 FZD4 NDP
5 normal MP:0002873 9.81 ATOH7 COL2A1 CTNNB1 FZD4 GFAP GLUL
6 pigmentation MP:0001186 9.61 ADAMTSL4 CTNNB1 FZD4 LRP5 NDP PDGFB
7 vision/eye MP:0005391 9.47 ADAMTSL4 ATOH7 COL2A1 CTNNB1 FZD4 GFAP

Drugs & Therapeutics for Retinal Detachment

Drugs for Retinal Detachment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Bevacizumab Approved, Investigational Phase 4 216974-75-3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Triazolam Approved, Investigational Phase 4 28911-01-5 5556
Rasagiline Approved Phase 4 136236-51-6 3052776
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
17 Sodium Channel Blockers Phase 4
18 Diuretics, Potassium Sparing Phase 4
19 Antineoplastic Agents, Immunological Phase 4
20 Neurotransmitter Agents Phase 4
21 Adrenergic alpha-Agonists Phase 4
22 Adrenergic Agents Phase 4
23 Adrenergic Agonists Phase 4
24 Anesthetics, General Phase 4
25 Anesthetics, Intravenous Phase 4
26 Immunoglobulins, Intravenous Phase 4
27 Immunoglobulin G Phase 4
28 Methylprednisolone Acetate Phase 4
29 Anesthetics Phase 4
30 Proxymetacaine Phase 4
31 Hypnotics and Sedatives Phase 4
32 Protective Agents Phase 4
33 Antirheumatic Agents Phase 4
34 Neuroprotective Agents Phase 4
35 Monoamine Oxidase Inhibitors Phase 4
36 Analgesics, Non-Narcotic Phase 4
37 Analgesics Phase 4
38 Cyclooxygenase Inhibitors Phase 4
39 Ketorolac Tromethamine Phase 4
40 Anti-Inflammatory Agents, Non-Steroidal Phase 4
Colchicine Approved Phase 3 64-86-8 6167 2833
Povidone-iodine Approved Phase 3 25655-41-8
Povidone Approved Phase 3 9003-39-8 131751496
Iodine Approved, Investigational Phase 3 7553-56-2 807
Dalteparin Approved Phase 3 9005-49-6
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
Fluorouracil Approved Phase 3 51-21-8 3385
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
Cadexomer iodine Experimental Phase 3 94820-09-4
50 Tubulin Modulators Phase 3

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
2 Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia Unknown status NCT01417572 Phase 4 lidocaine
3 On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD. Unknown status NCT01670162 Phase 4 Aflibercept
4 Comparison of Dexmedetomidine vs. Propofol in Vitreoretinal Surgery Under Sub-Tenon's Block Completed NCT01001429 Phase 4 Dexmedetomidine infusion;propofol
5 The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
6 Intravitreal Ranibizumab in Patients With Retinal Pigment Epithelial Detachments Secondary to Age-related Macular Degeneration Completed NCT00976222 Phase 4 intravitreal injection with ranibizumab
7 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
8 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
9 Open Label Study: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment. Completed NCT01722656 Phase 4 Aflibercept
10 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
11 A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration Completed NCT02142296 Phase 4 Eylea
12 Assessing the Efficacy and Safety of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment Recruiting NCT04464629 Phase 4 Dextenza;Prednisolone Acetate
13 Using Intraoperative Triamcinolone Acetonide Irrigation to Reduce Post-Operative Pain From Scleral Buckle Surgery Recruiting NCT04701593 Phase 4 Triamcinolone Acetonide 40mg/mL
14 Comparative Analysis of Oral Sedation Versus Standard Intravenous Sedation in Vitreoretinal Surgery With Topical Anesthesia and Sub-tenon's Block Not yet recruiting NCT04346095 Phase 4 Oral Sedatives with or Without Analgesia;Intravenous Sedatives with or Without Analgesia
15 Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment Terminated NCT02068625 Phase 4 Rasagiline;Placebo
16 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Terminated NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
17 Effect of Dexamethasone on Postoperative Symptoms of Scleral Buckling Surgery Patients: a Randomized Control Trial Withdrawn NCT01326585 Phase 4 Dexamethasone Sodium Phosphate Injection;Saline Injection
18 This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg Withdrawn NCT01495208 Phase 4 Aflibercept
19 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy. Withdrawn NCT01666236 Phase 4
20 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
21 Pressurized Perfluorocarbon Perfused 23 GA Vitrectomy in Complicated Diabetic Retinal Detachment Unknown status NCT00404209 Phase 3
22 Comparison of Two High-Density Silicone Oils in Complicated Rhegmatogenous Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
23 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
24 Comparison of Air and Expansile Gas in Pneumatic Retinopexy Completed NCT00120445 Phase 3
25 Randomized Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation for Retinopexy in Scleral Buckle Surgery Completed NCT01068379 Phase 3
26 Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy: Results of the Pan-American Collaborative Retina Study (PACORES) Group Completed NCT01976923 Phase 3 Intravitreal bevacizumab
27 Diabetic Retinopathy Vitrectomy Study (DRVS) Completed NCT00000154 Phase 3
28 The Silicone Study Completed NCT00000140 Phase 3 Perfluoropropane;Sulfur Hexafluoride;Silicone Oil
29 Determining Optimal Treatment Algorithms for Macular Degeneration Pigment Epithelial Detachments Treated With Intraocular Lucentis Completed NCT00590694 Phase 2, Phase 3 ranibizumab
30 Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Active, not recruiting NCT02834559 Phase 3 5-fluorouracil and low molecular weight heparin;Placebo
31 A Phase III Randomized 1:1, Masked, Study of the Safety, Tolerability, and Efficacy of Intravitreal Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Adjuvant Management of TRD and Vit Hem Associated With PDR Withdrawn NCT01589718 Phase 3 Macugen;Sham
32 Perfluorocarbon Gases for the Repair of Retinal Detachments. Unknown status NCT00161525 Phase 2
33 Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery Unknown status NCT01297816 Phase 2 placebo;Minocycline
34 Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function Completed NCT00972374 Phase 2 400 ug Brimonidine Implant;200 ug Brimonidine Implant
35 Bevacizumab Against Recurrent Retinal Detachment Completed NCT02192970 Phase 2 Bevacizumab
36 The Effect of Intravitreous Ranibizumab on Intra-Operative Bleeding During Pars Plana Vitrectomy for Diabetic Traction Retinal Detachment Completed NCT01201161 Phase 2 Ranibizumab
37 Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV for Diabetic Tractional Retinal Detachment (IBETRA Study) Completed NCT00690768 Phase 2 Bevacizumab
38 Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED) Completed NCT00841581 Phase 2 Ranibizumab
39 A Multi-Center, Randomized, Sham-Controlled, Phase II Trial Evaluating Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Macula Off Rhegmatogenous Retinal Detachment Repair (The PREVENT-PVR Trial) Recruiting NCT04580147 Phase 2 Intravitreal aflibercept injection
40 Head Positioning Duration After Retinal Detachment Repair With Vitrectomy and Gas Recruiting NCT03714503 Phase 2
41 Scleral Buckling for Retinal Detachment Prevention in Genetically Confirmed Stickler Syndrome : a Randomized Controlled Trial Not yet recruiting NCT04465188 Phase 2
42 A Randomized, Double-Masked, Placebo Controlled, Parallel Group, Multi-Center, Dose-Ranging Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Rhegmatogenous Retinal Detachment Terminated NCT00083967 Phase 2 denufosol tetrasodium (INS37217) Intravitreal Injection
43 High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study Terminated NCT01189019 Phase 2 ranibizumab;ranibizumab
44 The Multi-center Exploratory Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment Unknown status NCT01261533 Phase 1
45 Ursodeoxycholic Acid (UDCA) as Adjuvant Treatment for Rhegmatogenous Retinal Detachment: a Phase I Pilot Study Completed NCT02841306 Phase 1 Ursodeoxycholic Acid
46 A Double-Masked, Randomized, Dose-Ranging Study of a Single Intravitreal (IVT) Injection of INS37217 Intravitreal Injection in Subjects With Retinal Detachment Completed NCT00210067 Phase 1 denufosol tetrasodium (INS37217) Intravitreal Injection
47 A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy Completed NCT01487070 Phase 1 Macugen (Pegaptanib Sodium)
48 Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment Completed NCT00548197 Phase 1 Bevacizumab
49 Partial Posterior Hyaloidectomy in Macular Surgery : A Modified Procedure of Vitrectomy to Prevent Retinal Break Related to Induction of a Posterior Vitreous Detachment Completed NCT01454466 Phase 1
50 A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab. Completed NCT00749021 Phase 1 Ranibizumab;Ranibizumab;Ranibizumab;Ranibizumab

Search NIH Clinical Center for Retinal Detachment

Cochrane evidence based reviews: retinal detachment

Genetic Tests for Retinal Detachment

Genetic tests related to Retinal Detachment:

# Genetic test Affiliating Genes
1 Retinal Detachment 29

Anatomical Context for Retinal Detachment

MalaCards organs/tissues related to Retinal Detachment:

Eye, Retina, Endothelial, Bone, Lung, Brain, Breast

Publications for Retinal Detachment

Articles related to Retinal Detachment:

(show top 50) (show all 19404)
# Title Authors PMID Year
Incidence and surgical care of retinal detachment during the first SARS-CoV-2 lockdown period at a tertiary referral center in Austria. 61 42
33684142 2021
Immunological biomarkers of the vitreous responsible for proliferative alteration in the different forms of retinal detachment. 61 42
33371882 2020
Aflibercept for Vascularised Serous Pigment Epithelial Detachment: One-Year Anatomical and Functional Results. 42
33126803 2020
Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. 61 54
20465445 2010
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. 61 54
19643496 2009
The effects of transient retinal detachment on cavity size and glial and neural remodeling in a mouse model of X-linked retinoschisis. 54 61
19387072 2009
Resolution of persistent exudative retinal detachment in a case of Sturge-Weber syndrome with anti-VEGF administration. 54 61
19657986 2009
Upregulation of Semaphorin 3A and the associated biochemical and cellular events in a rat model of retinal detachment. 54 61
18815803 2009
Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis. 61 54
19668494 2007
Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening. 54 61
16679807 2006
Detection of PEDF in subretinal fluid of retinal detachment: possible role in the prevention of subretinal neovascularization. preliminary results. 61 54
16679806 2006
Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. 61 54
15635051 2005
High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. 54 61
15505063 2004
A case of Kniest dysplasia with retinal detachment and the mutation analysis. 61 54
14644246 2003
Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity. 61 54
14507768 2003
Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). 54 61
12845559 2003
Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. 54 61
12670875 2003
Up-regulation of glial fibrillary acidic protein in response to retinal injury: its potential role in glial remodeling and a comparison to vimentin expression. 61 54
14692684 2003
Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. 54 61
12208248 2002
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. 54 61
11914216 2002
Levels of basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in subretinal fluid from patients with retinal detachment. 54 61
11589877 2001
Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. 54 61
11264138 2001
Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment. 61 54
11110038 2000
Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. 54 61
10980138 2000
Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. 54 61
11148602 2000
Fibrinolytic activity of subretinal fluid after cryopexy. 54 61
10651193 1999
Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. 54 61
10067974 1999
Elevated vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. 54 61
12579655 1999
Ocular complications and a new surgical approach to lens dislocation in homocystinuria due to cystathionine-beta-synthetase deficiency. 61 54
9587034 1998
Vascular endothelial growth factor upregulation in human central retinal vein occlusion. 61 54
9499769 1998
[Concentration of vascular endothelial growth factor within the subretinal space and vitreous fluid in rhegmatogenous retinal detachment]. 54 61
9209137 1997
[Biological activity of subretinal fluid in selected in vitro tests]. 61 54
9685781 1997
Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. 61 54
7485392 1995
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. 61 54
7540233 1995
Glial fibrillary acidic protein and its mRNA: ultrastructural detection and determination of changes after CNS injury. 54 61
1486005 1992
Cytokines in proliferative vitreoretinopathy. 54 61
1800167 1991
Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment. 61
33787445 2021
The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery. 61
33510064 2021
Infectious necrotizing scleritis and proliferative vitreoretinopathy after scleral buckling in a patient with atopic dermatitis. 61
33748537 2021
Doppelgänger dilemma: Leiomyoma versus uveal melanoma. 61
33748534 2021
Case of peripheral fibrovascular proliferative retinopathy associated with morning glory disc anomaly. 61
33665476 2021
Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature. 61
33770016 2021
Pulmonary hamartoma: Feasibility of dual-energy CT detection of intranodular fat. 61
33680271 2021
Autosomal recessive Stickler syndrome associated with homozygous mutations in the COL9A2 gene. 61
33356723 2021
BACILLARY LAYER DETACHMENT IN ACUTE VOGT-KOYANAGI-HARADA DISEASE: A Novel Swept-Source Optical Coherence Tomography Analysis. 61
32833410 2021
A novel c.980C>G variant in OAT results in identifiable gyrate atrophy phenotype associated with retinal detachment in a young female. 61
33243052 2021
Urgency of retinal detachment repair: is it time to re-think our priorities? 61
32873942 2021
Chandelier-assisted pneumatic retinopexy for rhegmatogenous retinal detachment repair in young adults. 61
33727471 2021
32796447 2021
Exudative retinal detachment secondary to choroidal metastasis of lung carcinoma. 61
33358473 2021

Variations for Retinal Detachment

ClinVar genetic disease variations for Retinal Detachment:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RHO NM_000539.3(RHO):c.891C>G (p.Ser297Arg) SNV Pathogenic 523376 rs142285818 GRCh37: 3:129251570-129251570
GRCh38: 3:129532727-129532727
2 COL2A1 NM_001844.5(COL2A1):c.842_843insT (p.Gly282fs) Insertion Pathogenic 812293 rs1592230091 GRCh37: 12:48387804-48387805
GRCh38: 12:47994021-47994022
3 COL9A3 NM_001853.4(COL9A3):c.1107+1G>C SNV Likely pathogenic 973782 GRCh37: 20:61461034-61461034
GRCh38: 20:62829682-62829682
4 NDP-AS1 , NDP NM_000266.4(NDP):c.308_311dup (p.Lys104fs) Duplication Likely pathogenic 523342 rs1555976049 GRCh37: X:43809135-43809136
GRCh38: X:43949889-43949890
5 COL9A3 NM_001853.4(COL9A3):c.388G>A (p.Gly130Ser) SNV Likely pathogenic 392918 rs139401633 GRCh37: 20:61453127-61453127
GRCh38: 20:62821775-62821775
6 EYS NM_001142800.2(EYS):c.4152del (p.Pro1385fs) Deletion Uncertain significance 523414 rs1185686653 GRCh37: 6:65301608-65301608
GRCh38: 6:64591715-64591715

Expression for Retinal Detachment

Search GEO for disease gene expression data for Retinal Detachment.

Pathways for Retinal Detachment

Pathways related to Retinal Detachment according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
10 11.73 GFAP CTNNB1 COL2A1

GO Terms for Retinal Detachment

Cellular components related to Retinal Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 VEGFA SERPINF1 RS1 PDGFB PDGFA NDP
2 extracellular space GO:0005615 9.96 VEGFA SERPINF1 RS1 PDGFB PDGFA NDP
3 basement membrane GO:0005604 9.65 SERPINF1 COL9A3 COL2A1
4 collagen trimer GO:0005581 9.63 COL9A3 COL2A1 COL11A1
5 endoplasmic reticulum lumen GO:0005788 9.63 PDGFB PDGFA COL9A3 COL2A1 COL11A1 ADAMTSL4
6 platelet alpha granule lumen GO:0031093 9.54 VEGFA PDGFB PDGFA
7 glial cell projection GO:0097386 9.43 GLUL GFAP
8 extracellular matrix GO:0031012 9.43 VEGFA NDP COL9A3 COL2A1 COL11A1 ADAMTSL4
9 Wnt signalosome GO:1990909 9.4 LRP5 CTNNB1
10 collagen-containing extracellular matrix GO:0062023 9.17 SERPINF1 PDGFB NDP COL9A3 COL2A1 COL11A1

Biological processes related to Retinal Detachment according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.1 VEGFA RS1 PDGFB PDGFA LRP5 FZD4
2 positive regulation of cell proliferation GO:0008284 10.02 VEGFA PDGFB PDGFA LRP5 CTNNB1
3 nervous system development GO:0007399 10.01 VEGFA NDP LDB2 CTNNB1 ATOH7
4 angiogenesis GO:0001525 9.91 VEGFA TSPAN12 PDGFA GLUL
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.79 VEGFA PDGFB PDGFA
6 positive regulation of MAPK cascade GO:0043410 9.78 VEGFA PDGFB PDGFA CTNNB1
7 response to wounding GO:0009611 9.77 PDGFB PDGFA GFAP
8 Wnt signaling pathway GO:0016055 9.77 TSPAN12 NDP LRP5 FZD4 CTNNB1
9 canonical Wnt signaling pathway GO:0060070 9.76 LRP5 FZD4 CTNNB1
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.76 NDP LRP5 FZD4 CTNNB1
11 vasculogenesis GO:0001570 9.74 VEGFA FZD4 CTNNB1
12 positive regulation of MAP kinase activity GO:0043406 9.72 VEGFA PDGFB PDGFA
13 visual perception GO:0007601 9.72 RS1 RHO NDP COL2A1 COL11A1
14 heart morphogenesis GO:0003007 9.7 VEGFA COL2A1 COL11A1
15 positive regulation of cell division GO:0051781 9.69 VEGFA PDGFB PDGFA
16 gastrulation with mouth forming second GO:0001702 9.63 LRP5 CTNNB1
17 positive regulation of DNA biosynthetic process GO:2000573 9.63 VEGFA PDGFB
18 negative regulation of platelet activation GO:0010544 9.59 PDGFB PDGFA
19 proteoglycan metabolic process GO:0006029 9.58 COL2A1 COL11A1
20 positive regulation of protein autophosphorylation GO:0031954 9.58 VEGFA PDGFB PDGFA
21 retinal blood vessel morphogenesis GO:0061304 9.54 LRP5 FZD4
22 positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway GO:0035793 9.49 PDGFB PDGFA
23 negative regulation of phosphatidylinositol biosynthetic process GO:0010512 9.43 PDGFB PDGFA
24 retina vasculature morphogenesis in camera-type eye GO:0061299 9.43 NDP LRP5 FZD4
25 extracellular matrix-cell signaling GO:0035426 9.33 NDP LRP5 FZD4
26 positive regulation of mesenchymal cell proliferation GO:0002053 9.26 VEGFA PDGFA LRP5 CTNNB1
27 extracellular matrix organization GO:0030198 9.17 PDGFB PDGFA GFAP COL9A3 COL2A1 COL11A1

Molecular functions related to Retinal Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent conferring tensile strength GO:0030020 9.43 COL9A3 COL2A1 COL11A1
2 Wnt-activated receptor activity GO:0042813 9.33 TSPAN12 LRP5 FZD4
3 growth factor receptor binding GO:0070851 9.32 PDGFB PDGFA
4 platelet-derived growth factor receptor binding GO:0005161 9.13 VEGFA PDGFB PDGFA
5 platelet-derived growth factor binding GO:0048407 8.8 PDGFB PDGFA COL2A1

Sources for Retinal Detachment

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....